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AbstrAct
To update the evidence on efficacy and safety of non-
pharmacological, pharmacological and surgical interventions 
for hand osteoarthritis (OA), a systematic literature review 
was performed up to June 2017, including (randomised) 
controlled trials or Cochrane systematic reviews. Main efficacy 
outcomes were pain, function and hand strength. Risk of 
bias was assessed. Meta-analysis was performed when 
advisable. Of 7036 records, 127 references were included, 
of which 50 studies concerned non-pharmacological, 64 
pharmacological and 12 surgical interventions. Many studies 
had high risk of bias, mainly due to inadequate randomisation 
or blinding. Beneficial non-pharmacological treatments 
included hand exercise and prolonged thumb base splinting, 
while single trials showed positive results for joint protection 
and using assistive devices. Topical and oral non-steroidal 
anti-inflammatory drugs (NSAiDs) proved equally effective, 
while topical NSAiDs led to less adverse events. Single trials 
demonstrated positive results for chondroitin sulfate and intra-
articular glucocorticoid injections in interphalangeal joints. 
Pharmacological treatments for which no clear beneficial 
effect was shown include paracetamol, intra-articular thumb 
base injections of glucocorticoids or hyaluronic acid, low-dose 
oral glucocorticoids, hydroxychloroquine and anti-tumour 
necrosis factor. No trials compared surgery to sham or non-
operative treatment. No surgical intervention for thumb base 
OA appeared more effective than another, although in general 
more complex procedures led to more complications. No 
interventions slowed radiographic progression. in conclusion, 
an overview of the evidence on efficacy and safety of 
treatment options for hand OA was presented and informed 
the task force for the updated european League Against 
Rheumatism management recommendations for hand OA.
InTroduCTIon
In 2007, the first European League Against 
Rheumatism (EULAR) recommendations for 
the management of hand osteoarthritis (OA) 
were published, based on expert opinion and 
an overview of the literature.1 Many proposi-
tions, however, were based mainly on expert 
opinion, as evidence was lacking.
Despite it being a prevalent disease, for years, 
options to treat patients with hand OA have 
been limited. In search of better alternatives 
for symptom relief, and in hopes of finding 
a disease-modifying anti-osteoarthritic drug, 
many clinical trials have been performed in 
the last decade, expanding the possible range 
of therapeutic options. At the same time, data 
have become available showing that some treat-
ments which were believed to be beneficial do 
Key messages
What is already known about this subject?
 ► The first european League Against Rheumatism 
(eULAR) recommendations for the management of 
hand osteoarthritis were published in 2007, based 
on expert opinion and available literature at that 
time.
What does this study add?
 ► Since 2007 many new trials were published in the 
hand osteoarthritis field.
 ► This systematic literature review provides an updat-
ed overview of the current evidence on efficacy and 
safety of non-pharmacological, pharmacological and 
surgical treatment options for hand osteoarthritis.
How might this impact on clinical practice?
 ► This systematic literature review informed the task 
force for the 2018 update of the eULAR recommen-
dations for the management of hand osteoarthritis.
 o
n
 9 August 2019 at W
alaeus Library. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2018-000734 on 11 O
ctober 2018. Downloaded from
 
2 Kroon FPB, et al. RMD Open 2018;4:e000734. doi:10.1136/rmdopen-2018-000734
RMD Open
not appear to be efficacious after all. New evidence has 
emerged on various therapies, including but not limited 
to self-management, application of thumb base splints, 
topical non-steroidal anti-inflammatory drugs (NSAIDs), 
oral corticosteroids, various intra-articular therapies and 
treatment with conventional and biological disease-modi-
fying anti-rheumatic drugs (cs/bDMARDs), for example, 
hydroxychloroquine and tumour necrosis factor (TNF) 
inhibitors.
In light of the newly accrued data, it was therefore time 
to update the 2007 management recommendations. This 
paper presents the systematic literature review (SLR) that 
accompanies the update of the recommendations. The 
aim of this SLR was to inform the task force on the current 
evidence for efficacy and safety of all non-pharmacological, 
pharmacological and surgical treatments for hand OA.
MeTHods
search strategy
A systematic search was conducted in PubMed/
MEDLINE, Embase and the Cochrane CENTRAL 
databases up to 6 June 2017. Additionally, conference 
abstracts of the EULAR, American College of Rheuma-
tology (ACR) and OsteoArthritis Research Society Inter-
national (OARSI) annual conferences of the last two 
years, and reference lists of included studies and other 
relevant SLRs were screened. The search strategy can be 
found in the online supplementary file 1. Eligible study 
types were randomised controlled trials (RCTs) and clin-
ical controlled trials (CCTs). Observational longitudinal 
studies were considered to assess safety, and to assess effi-
cacy of surgical interventions, but only if a comparator 
group was available and the number of participants per 
group was at least 50. Cochrane systematic reviews were 
also included. The following hierarchy of study design 
was adopted to assess the evidence for each interven-
tion: Cochrane systematic reviews, RCTs, CCTs and lastly 
observational studies.
Research questions were formulated according to 
the PICO format: Participants, Interventions, Compar-
ators, Outcomes.2 Studies of any non-pharmacological, 
pharmacological or surgical intervention in adults diag-
nosed with hand OA were included. Studies including 
participants with other diagnoses were only eligible for 
inclusion if the results were presented separately for 
participants with hand OA. The comparator could be 
placebo, care-as-usual, any other non-pharmacological, 
pharmacological or surgical intervention, or the same 
intervention in a different dose, formulation, regimen or 
treatment duration. Studies without a comparator were 
excluded. Other exclusion criteria were a total number 
of participants in non-surgical trials <20 and premature 
termination of the trial.
Efficacy outcomes were considered as proposed by 
the OMERACT core set for domains in clinical trials for 
hand OA.3 Main efficacy outcomes were pain (preferably 
measured on visual analogue scale (VAS), numerical rating 
scale (NRS), or a validated questionnaire, eg, Austra-
lian/Canadian Hand Osteoarthritis Index (AUSCAN) or 
Michigan Hand Outcomes Questionnaire (MHQ)), hand 
function (validated questionnaire, eg, Functional Index 
for Hand OsteoArthritis (FIHOA), AUSCAN or MHQ) 
and hand strength (grip or pinch strength). Additional 
efficacy outcomes that were considered included patient 
global assessment (VAS or NRS), health-related quality 
of life (Short-Form 36, EuroQoL), structural damage, 
hand mobility (Hand Mobility in Scleroderma test, modi-
fied Kapandji index, fingertip-to-palm-distance) and the 
number of participants fulfilling the OMERACT-OARSI 
responder criteria.4 The primary safety outcome was with-
drawals due to adverse events (AEs). In addition, serious 
AEs and AEs broken up by bodily system (eg, gastrointes-
tinal, cardiovascular) were assessed. Studies that did not 
assess any efficacy or safety outcomes were excluded.
study selection, data extraction and risk of bias assessment
One reviewer (FK) screened titles and abstracts to deter-
mine eligibility for inclusion, according to predefined 
inclusion criteria, followed by full-text review where neces-
sary. In case of doubt, a second reviewer was consulted 
(MK/LC). Relevant data on study characteristics, inter-
ventions, study population and the above-mentioned 
outcomes was extracted (FK). The risk of bias (RoB) 
was assessed with regard to random sequence genera-
tion, allocation concealment, blinding (participants, 
care provider, outcome assessor), incomplete outcome 
data, selective outcome reporting and other sources of 
bias according to the ‘Cochrane tool’ (FK).5 Each item 
was judged as low (green colour), high (red) or unclear 
RoB (yellow; lack of information or uncertainty over 
potential bias). An ‘overall assessment’ for each study was 
based on the judgements for each RoB item. Selection 
bias (sequence generation, allocation concealment) and 
blinding were considered ‘key domains’, that is, the most 
important domains in a study’s RoB.
data analysis
Data were only pooled in case of sufficient clinical and 
statistical homogeneity. For continuous outcomes, data 
were summarised as mean difference (MD) with corre-
sponding 95% CI, unless different measurement instru-
ments were used to measure the same outcome, in which 
case standardised mean differences were calculated. A 
random effects model was used. Studies that could not be 
included in the meta-analysis are presented descriptively. 
Stata V.14.1 was used for meta-analysis.
resulTs
The literature search yielded 5020 records (after de-du-
plication), of which 127 references were included in 
this review (see figure 1 and online supplementary table 
S1). Three studies were additionally excluded because 
of language (Turkish, Chinese). In total, 50 studies 
assessed benefits and harms of different non-pharma-
cological therapies, including one Cochrane review. 
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Figure 1 Flow chart of systematic literature review. ACR, American College of Rheumatology; EULAR, European League 
Against Rheumatism; OARSI, Osteoarthritis Research Society International.
Pharmacological interventions were investigated in 64 
studies, including one observational study. Surgical inter-
ventions were assessed in 11 trials, all summarised in one 
Cochrane review.
non-pharmacological interventions
Table 1 presents an overview of the characteristics and 
RoB of the 28 studies of the most relevant non-pharma-
cological interventions to inform the 2018 update of the 
EULAR management recommendations for hand OA. 
The remaining trials studied thermal modalities (n=3), 
manual therapy (n=3), balneotherapy (n=6), low-level 
laser therapy (n=4), yoga (n=1), nuclear magnetic reso-
nance (n=1), magnetotherapy (n=1), leeches (n=1) and 
alkalinisation of diet (n=1), and are described in online 
supplementary tables (3.1.5, 3.1.7, 3.1.9, 3.1.11).
The studies were heterogeneous, especially with respect 
to type of intervention, study duration (range: 1 week 
to 1 year, most up to 8 weeks) and assessed outcomes. 
Most were RCTs (n=19), and a minority CCTs (n=3) or 
cross-over trials (n=6). Many studies were small: 15 trials 
(54%) included 60 participants or less. All studies were 
judged to be at high or unclear RoB, most often due to 
lack of blinding. A detailed RoB assessment is presented 
in online supplementary tables 3.1.1-3.1.12
Table 2 presents an overview of the main results of 
the most relevant non-pharmacological trials for which 
the outcomes pain, function, fulfilment of OARSI-
OMERACT criteria4 or grip strength could be assessed. 
Safety outcomes are presented in online supplemen-
tary table 4.1. If studies were pooled, results are also 
presented in forest plots (online supplementary figures 
S1-S8).
In summary, exercise leads to beneficial effects on 
hand pain, function, joint stiffness and grip strength, 
although effect sizes are small. Few (non-severe) AEs 
were reported, showing a signal for increased number 
of AEs in participants undergoing exercise therapy, in 
particular increased joint inflammation and hand pain 
(RR 4.6 (95% CI 0.5 to 39.3); online supplementary table 
4.1).6
Joint protection led to a higher proportion of partic-
ipants being classified as responder to treatment 
according to OARSI-OMERACT criteria after 6 months, 
though mean AUSCAN pain and function subscales did 
not differ between groups.7
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On the short term, thumb base splinting did not lead to 
pain relief or functional improvement,8–12 though studies 
assessing long-term use showed that this was associated 
with more pain relief and improved function (online 
supplementary figures S1-S4).10 12 Studies assessed many 
different types of splints (eg, short or long, custom-made 
or prefabricated, neoprene or thermoplast or other 
material) and instructions for use (eg, during activities 
of daily living, at night, constantly). Only short versus 
long thumb base splints (ie, including only CMC joint vs 
both CMC and MCP joint) could formally be compared 
and were not associated with different clinical outcomes 
(online supplementary figures S5-S6).13–15 For other 
splint types or instructions, no consistent benefit of one 
over another could be identified in RCTs/CCTs or cross-
over studies.16–20 A single study assessed night-time DIP 
splinting specifically, but did not show improvements in 
pain, function or pinch strength after 3 months.21
Use of assistive devices led to small improvements in 
function, as measured with the patient-specific Canadian 
Occupational Performance Measure (COPM) and the 
AUSCAN function subscale, but not in pain.22
Several studies assessed different combination 
programmes of multiple non-pharmacological inter-
ventions.7 15 23–28 Three trials compared a programme 
including education, joint protection and hand exercises 
to education alone, and though no formal meta-anal-
ysis could be performed, no between-group differences 
in pain, function or grip strength could be confirmed 
(online supplementary figures S7-S8).7 25 26 The other 
studies of combination programme were more hetero-
geneous, especially in the type of intervention studied. 
Some reported positive effects of the combination versus 
non-combination interventions, especially on subjec-
tive measures like pain,23 28 and not on more objective 
measures like hand strength,24 28 though others reported 
no between-group differences.15 27
Furthermore, application of heat was assessed in three 
heterogeneous trials, both in design and type of interven-
tion (high RoB). Two studies reported improvements in, 
for example, pain and grip strength in the intervention 
group compared with control,29 30 and one cross-over trial 
reported no between-group differences.31 Three studies 
(high RoB) focused on different forms of manual therapy 
in elderly, severe CMC patients with OA (mean age 81.4 
years) and showed positive effects on pain sensitivity and 
hand strength in the intervention group compared with 
control, both in the treated, symptomatic hand, and in 
the contralateral non-treated non-symptomatic hand.32–37 
Finally, six studies (five high RoB, one unclear RoB) 
assessed different forms of balneotherapy to another active 
intervention,38–40 sham intervention41 42 or usual care.43 
The studies comparing balneotherapy to another active 
intervention or to usual care all report positive effects 
of balneotherapy on pain, function and hand strength 
compared with the chosen control group.38–40 43 However, 
balneotherapy (mud application or mineral thermal bath) 
was not convincingly better than a sham intervention.41 42
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Pharmacological interventions
Table 3 presents an overview of the characteristics and 
RoB of the 33 trials of the most relevant pharmacological 
interventions to inform the 2018 update of the EULAR 
management recommendations for hand OA. Trials not 
listed in table 3 studied topical capsaicin (n=1), topical 
salicylates (n=2), paracetamol (n=4), glucosamine (n=1), 
diacerhein (n=1), different herbal formulations (n=3), 
anti-interleukin-1 (n=1), clodronate (n=1), several types 
of periarticular injections (n=3), intra-articular hyalu-
ronic acid (n=9), other intra-articular therapies (n=2), 
folate/cobalamin supplementation (n=1), apremilast 
(n=1), galactosaminoglycuronglycan sulfate (n=1), and 
pregabalin and duloxetine (n=1). A description can be 
found in online supplementary tables (3.2.2, 3.2.4, 3.2.6, 
3.2.10, 3.2.12, 3.2.15, 3.2.17, 3.2.22).
The longest trial lasted up to 3 years, though most 
trials had a duration of 3 weeks. Most studies focused 
on clinical outcomes, while structure modification was 
the primary outcome of two trials.44 45 The majority were 
RCTs (n=30), and few were set-up as CCTs (n=1) or cross-
over trials (n=2). Seven trials specifically included partic-
ipants with signs of 'inflammatory OA', all investigating 
anti-inflammatory agents (ie, NSAIDs, glucocorticoids 
and anti-TNF).45–51 Compared with non-pharmacolog-
ical interventions, less studies were small (n≤60; 15 trials, 
45%). Twelve studies (36%) were at low RoB. Reason to 
judge studies to be at high or unclear RoB was most often 
due to problems with randomisation or blinding, and for 
six studies only a conference abstract was available thus 
RoB remained unclear. The detailed RoB assessment is 
presented in online supplementary (3.2.1–3.2.23).
Table 4 presents an overview of the main results of 
the most relevant pharmacological trials for which 
the outcomes pain, function, fulfilment of OARSI-
OMERACT criteria4 or grip strength could be assessed. 
Safety outcomes are presented in online supplementary 
table 4.2. Forest plots of pooled results are presented in 
online supplementary figures S9-S20.
Topical pharmacological interventions
Topical diclofenac gel was shown to be superior to placebo 
in a large RCT (low RoB), leading to small improvements 
in pain and function, and not more AEs, after 8 weeks.52 
Topical NSAIDs led to similar pain relief as oral NSAIDs,50 51 
yet lower risk of any AE (RR 0.40 (95% CI 0.09 to 1.74)),50 51 
gastrointestinal AEs (RR 0.64 (0.35 to 1.20)),51 severe AEs 
(RR 0.54 (0.17 to 1.71)),51 and withdrawals due to AEs (RR 
0.15 (0.03 to 0.63)) (online supplementary table 5.2, figures 
S9-S11).51 Pooled safety data from two RCTs comparing 
topical diclofenac gel to placebo in patients with hand OA 
showed similar and low rates of AEs in subgroups at low 
versus high risk of NSAID-related AEs (ie, age ≥65 years, 
and with comorbid hypertension, type 2 diabetes or cere-
brovascular or cardiovascular disease).53 A trial (low RoB) 
comparing topical ibuprofen cream to arnica cream found 
no between-group differences.54 Two studies (one high 
RoB, one unclear RoB) comparing topical NSAIDs with a 
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non-pharmacological treatment reported superiority of the 
comparator.39 55 Topical capsaicin was assessed in one RCT 
(unclear RoB), reporting better pain relief than placebo at 
the cost of increased risk of local AEs (burning and stinging 
sensation, RR 3.1 (95% CI 1.1 to 8.5)), which likely also 
compromised the trial’s success of blinding.56 A single 
application of topical salicylates was reported in two trials 
(high RoB) to lead to improvements in pain and stiffness, 
but also numerically more local AEs.57 58
Oral analgesics
Paracetamol was included as a treatment arm in three 
conference abstracts (unclear RoB) and one cross-over 
trial (high RoB), in various dosages and for different 
duration.48 59–61 Three trials intended paracetamol to be 
the control group. One trial (unclear RoB) included a 
placebo arm, and reports no between-group difference 
in pain or morning stiffness.59 Paracetamol was not supe-
rior to any of the active comparators.48 60 61
Oral NSAIDs lead to moderate improvements in 
pain and function compared with no intervention,49 
placebo62–64 and other active interventions (glucos-
amine/chondroitin sulfate,65 paracetamol48).
Nutraceuticals
The effectiveness of chondroitin sulfate was studied in two 
papers. One trial (low RoB) focused on clinical outcomes 
after 6 months, reporting beneficial effects on pain and 
function compared with placebo.66 The other study (high 
RoB) assessed structural outcomes in two long-term trials 
(published in one paper), assessing chondroitin sulfate 
and chondroitin polysulphate.44 Only for chondroitin 
polysulphate, a preparation not commercially available, 
less erosive damage after 3 years was reported and not for 
chondroitin sulfate. The trials did not report higher risk 
of sAEs in the intervention groups.
Glucosamine is reported to have beneficial effects on 
pain and function after 6 weeks in an RCT (unclear RoB) 
published as conference abstract (no raw data provided).61
Diacerhein was not better than placebo for pain 
relief or any of the other secondary outcomes in a study 
(unclear RoB) of Korean patients with hand OA, while 
more (mild) AEs were reported in the intervention 
group, especially discoloration of urine (88% vs 20%) 
and abdominal pain (31% vs 14%), but remarkably not 
diarrhoea (21% vs 20%).67
intra-articular treatments
Several intra-articular therapies were assessed, of which 
glucocorticoids and hyaluronic acid are the most 
commonly used. Intra-articular injection of glucocorti-
coids in the thumb base was not more beneficial than 
placebo with respect to pain and function (online supple-
mentary figures S12-13),68–70 while in one study (low 
RoB) participants reported less pain during movement 
and soft swelling after intra-articular glucocorticoid injec-
tion in IP joints.71 However, the latter study did not find 
beneficial effects on pain in rest or function.
Intra-articular injection of hyaluronic acid in the 
thumb base did not lead to improvements in pain or 
function compared with placebo (online supplementary 
figure S14).68 69 72 Six trials (four high RoB, two unclear 
RoB) compared intra-articular thumb base injection of 
glucocorticoids to hyaluronic acid, but no consistent 
beneficial effect of one treatment over the other could be 
shown.68 69 73–76 Single studies (two high RoB, two unclear 
RoB) assessed alternative dosages (ie, one, two or three 
hyaluronic acid injections,77 low vs high molecular weight 
hyaluronic acid78) and therapies (ie, intra-articular inflix-
imab,79 dextrose80) and are not described in depth.
Glucocorticoids and conventional or biological DMARDs
Short-term treatment with low-dose oral glucocorti-
coids were evaluated in two RCTs (low RoB). Six-week 
treatment with prednisolone/dipyridamole led to more 
improvement in pain (MD 12.3 (95% CI 3.0 to 21.5) on 
100 mm VAS), at the cost of more withdrawals due to 
AEs (38% vs 15%), mostly due to headache.81 In a trial 
of 4-week treatment with prednisolone 5 mg, however, no 
between-group differences were observed (eg, 100 mm 
VAS pain 19.9 mm in prednisolone vs 16.8 mm in placebo 
group).82 Results could not be combined due to clinical 
heterogeneity and remain inconclusive.
Three RCTs (unclear RoB), only published as confer-
ence abstracts, show that hydroxychloroquine does not 
have beneficial effects on pain (online supplementary 
figure S15), function, grip strength or radiographic 
progression (only assessed by Kingsbury et al).59 83 84 One 
trial also included a paracetamol arm and found no 
between-group differences compared with hydroxychlo-
roquine on pain (MD 2.5 (95% CI −9.9 to 14.9) on 100 
mm VAS, in favour of paracetamol).59
Four studies (two unclear RoB, two low RoB) 
assessed the efficacy of different TNF inhibitors (adali-
mumab45 46 85 and etanercept47 86 87), but no beneficial 
effect over placebo could be shown on pain, function or 
grip strength (online supplementary figures S16-20).
 Two studies (one unclear RoB, one low RoB) report 
less erosive radiological progression after 1 year in 
treated joints with soft tissue swelling at baseline (no data 
to pool).45 47 One RCT (low RoB) and one cross-over trial 
(unclear RoB) report no between-group differences in 
MRI synovitis, while only the RCT found a decrease in 
bone marrow lesions and the cross-over trial did not.46 87
surgical interventions
A Cochrane review summarised all available trials of 
thumb base surgery.88 No trials compared surgery to 
sham surgery or non-operative treatment. The trials all 
compared different surgical interventions for thumb 
base OA. Most trials compared trapeziectomy with and 
without ligament reconstruction tendon interposition 
(LRTI), but there was no difference in pain (three trials 
with 162 participants, MD −2.8 (95% CI −9.8 to 4.2) on 
100 mm VAS) or function (three trials with 211 partici-
pants, SMD 0.01 (95% CI −0.30 to 0.32)), while the risk 
 o
n
 9 August 2019 at W
alaeus Library. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2018-000734 on 11 O
ctober 2018. Downloaded from
 
15Kroon FPB, et al. RMD Open 2018;4:e000734. doi:10.1136/rmdopen-2018-000734
Osteoarthritis
for more complications was increased in the trapeziec-
tomy with LRTI groups (RR 1.9 (95% CI 0.96 to 3.7)). 
Single, low-quality studies compared other surgical inter-
ventions to each other, but did not show that one inter-
vention was clearly superior over another in terms of effi-
cacy or complication rate. Most importantly, compared 
with trapeziectomy, both arthrodesis (one trial, 37 partic-
ipants) and joint replacement surgery (one trial, 26 
participants) did not lead to different clinical outcomes. 
No studies of IP joint surgery could be included in our 
review.
dIsCussIon
This SLR summarises the current evidence for efficacy 
and safety of all non-pharmacological, pharmacological 
and surgical treatments for hand OA. Non-pharmaco-
logical treatments that were shown to result in symptom 
relief included hand exercise and prolonged splinting of 
the thumb base, while single trials showed positive results 
for joint protection and use of assistive devices. However, 
the RoB in most trials was high, mainly due to lack of 
blinding and effect sizes were modest. Pharmacological 
treatments that most evidently proved to be efficacious 
in relieving symptoms were NSAIDs, both topical and 
oral preparations, as assessed in high-quality trials. Single 
trials, also judged to be at low RoB, reported beneficial 
results for chondroitin sulfate and intra-articular injec-
tions of glucocorticoids in interphalangeal OA. Also for 
pharmacological interventions, effect sizes were modest, 
as considered using the cut-offs proposed by Cohen et al 
(ie, 0.2 representing a small,>0.5 a moderate and >0.8 a 
large effect).89 The effect of oral NSAIDs on pain, with an 
SMD of 0.4, was the largest effect. Taking an effect size of 
0.37 as a minimal clinically important difference (MCID; 
based on the median MCID in four recent OA trials90), 
corresponding to 9 mm on a 100 mm VAS, only the 
effects of prolonged thumb base splinting, oral NSAIDs 
and intra-articular glucocorticoid injections in inter-
phalangeal joints crossed the margin of clinical mean-
ingful difference. Promising pharmacological treatments 
for which no clear beneficial effect was demonstrated 
include paracetamol, intra-articular injections of gluco-
corticoids or hyaluronic acid in the thumb base joint, 
low-dose oral glucocorticoids, hydroxychloroquine and 
TNF inhibitors. Disease-modifying properties, especially 
radiographic progression, were studied in only a few 
trials. No convincing effects were found for the formu-
lations investigated, namely chondroitin sulfate (one 
trial) and TNF inhibitors (two trials). A signal for less 
erosive damage after 1 year of treatment with anti-TNF 
was reported in subgroup analyses of joints with clinical 
signs of inflammation at baseline in two separate trials, 
yet studies powered for this research question have not 
been performed to confirm this finding.
Safety was also evaluated in this SLR, though it should 
be noted that this outcome is best studied in large long-
term observational studies with high-quality follow-up 
since RCTs are usually underpowered to assess this 
outcome and include a more selected population. 
Although we aimed to include observational studies for 
this purpose, we did not find any with our search strategy. 
Based on this SLR, it is therefore not possible to draw 
strong conclusions on the safety aspect of many of the 
assessed therapies. Importantly, the included trials of 
topical and oral NSAIDs showed that, while no difference 
in efficacy could be proven, topical NSAIDs were indeed 
associated with less AEs than oral NSAIDs. Furthermore, 
no increased risk of AEs was shown for topical NSAIDs 
compared with placebo. These observations support 
topical NSAIDs as a useful option for first-line pharmaco-
logical treatment. Regarding surgical options, no specific 
intervention for thumb base OA appeared more effective 
than another, although in general more complex proce-
dures led to more complications.
The trials included in this review were rather heteroge-
neous in many aspects, for example in the type of inter-
vention, study duration, and assessed outcomes. This 
precluded meta-analysis in most instances. Some more 
recently published trials assessed more of the outcome 
measures summarised in the OMERACT core set for 
domains in clinical trials for hand OA.3 A core set for the 
instruments best used to measure these core domains is 
still underway. It may be expected that such a core set of 
instruments will help to harmonise outcome assessment 
in future clinical trials, which will ultimately improve the 
assessment of new treatment options.
Despite the large increase in the amount of trials 
published in the field of hand OA since the previous 
EULAR management recommendations in 2007 (39 out 
of 50 and 43 out of 64 included trials of non-pharmaco-
logical and pharmacological therapies, respectively, were 
published in 2007 or later), some important questions 
remain. For example, placebo-controlled trials of thumb 
base splints, paracetamol, tramadol and surgery (both for 
thumb base and interphalangeal OA) are lacking. More-
over, while some trials specifically include a subset of 
participants with OA of the thumb base, or with 'inflam-
matory' or 'activated' (finger) OA, more trials targeting 
specific subsets of patients expected to respond to the 
investigated treatment are needed. Furthermore, many 
studies were assessed to be at high RoB, often due to lack 
of blinding or inadequate method of randomisation. So 
although the number of trials may have increased, their 
quality is not consistent. For some interventions, especially 
non-pharmacological therapies, it is difficult to perform 
a double-blind trial, and therefore the evidence currently 
available is probably the best we can get. Recently, the 
Consolidated Standards of Reporting Trials has issued 
a statement addressing methodological issues specific 
to trials of non-pharmacological treatments to provide 
more guidance in this respect.91 However, other inter-
ventions, especially pharmacological therapies, are more 
easily studied in a double-blind fashion, and therefore, 
well-performed trials are needed and may change the 
conclusions of this review, for example, for paracetamol.
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This SLR has a few strengths, most importantly the 
methodological rigour with which it was performed, and 
the presentation of a comprehensive summary of the vast 
amount of data on the management of hand OA that 
has accrued so far. However, some limitations have to be 
acknowledged. Study selection and data extraction was 
performed by one reviewer author, whereas this should 
ideally be performed by two independent persons. Many 
studies were only published as a conference abstract at 
the time of manuscript preparation, precluding an assess-
ment of the RoB (now categorised as ‘unclear’).
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